Innate Pharma (IPHA) Total Liabilities (2017 - 2025)

Innate Pharma has reported Total Liabilities for 9 years, with the latest figure at $98.3 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities fell 10.04% year-over-year to $98.3 million; the trailing twelve-month figure through Dec 2025 stood at $98.3 million (down 10.04% YoY), and the FY2025 full-year result was $98.3 million, down 10.04% from the prior year.
• Total Liabilities for Q4 2025 stood at $98.3 million, down from $109.2 million in the prior quarter.
• The five-year high for Total Liabilities was $183.1 million in Q4 2021, with the low at $98.3 million in Q4 2025.
• Historically, Total Liabilities has averaged $136.0 million across 5 years, with a median of $132.6 million in 2023.
• Annual changes were most pronounced in 2021 — Total Liabilities climbed 1.4% — and 2024, when it decreased 17.65%.
• Innate Pharma's Total Liabilities stood at $183.1 million in 2021, then retreated by 14.35% to $156.8 million in 2022, then retreated by 15.42% to $132.6 million in 2023, then fell by 17.65% to $109.2 million in 2024, then slipped by 10.04% to $98.3 million in 2025.
• The last three Total Liabilities figures came in at $98.3 million (Q4 2025), $109.2 million (Q4 2024), and $132.6 million (Q4 2023), per Business Quant data.